Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 […]
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men Read More »